logo-loader

Admedus in trading halt with sale transaction news pending

Last updated: 13:22 10 Apr 2019 AEST, First published: 23:22 09 Apr 2019 AEST

1554866875_shutterstock_744046954
Shares last traded at 9.2 cents per share

Admedus Ltd (ASX:AHZ) is in a trading halt pending an announcement regarding an Admedus Immunotherapies sale transaction and a response to price query from the ASX.

The company’s securities will remain in trading halt until Friday April 12, 2019 or when the announcement is made to market.

READ: Admedus delivers results with heart-driven corporate strategy

Early last month Admedus received regulatory approval in the form of the CE Mark for its CardioCel 3D product portfolio and its collagen bioscaffold VascuCel in Europe.

The company intends to begin the first phase of its commercial launch of CardioCel 3D after having worked with selected key opinion leaders familiar with the technology.

Anteris talks market superiority of its biomimetic TAVR valve

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the company’s early feasibility study (EFS) to evaluate DurAVR™ THV. This unique device represents a new class of biomimetic valve and stands as the world's...

on 31/10/23